Related Experiment Video
Updated: Jun 18, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
Characteristics of COVID-19 vaccinated and unvaccinated patients admitted to Careggi University Hospital, Florence,
Riccardo Paggi1, Anna Barbiero1, Tommaso Manciulli1
1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Insights
COVID-19 vaccinated patients, even those with breakthrough infections, showed similar outcomes to unvaccinated individuals. However, vaccinated patients lacking antibodies had higher mortality, emphasizing the need for early treatment in vulnerable groups.
Area of Science:
- Immunology
- Epidemiology
- Public Health
Background:
- Over 11.5 billion COVID-19 vaccine doses administered globally.
- Vaccine effectiveness against severe disease is high (89.0%), but breakthrough infections occur.
- Fragile populations remain at risk for severe outcomes despite vaccination.
Purpose of the Study:
- To evaluate COVID-19 outcomes in vaccinated versus unvaccinated patients in a real-world setting.
- To investigate the impact of serological status on outcomes among vaccinated individuals.
- To identify factors influencing in-hospital mortality and resource utilization.
Main Methods:
- Real-world observational study of 420 COVID-19 admitted patients (July 2021-January 2022).
- Collected data on vaccination status, SARS-CoV-2 serology, treatments, oxygen support, ICU/sub-ICU admissions, length of stay, and mortality.
- Compared outcomes between vaccinated (Vg) and unvaccinated (UVg) groups, and stratified vaccinated patients by serological status.
Main Results:
- Vg had higher Charlson Comorbidity Index than UVg; no significant differences in mortality, LoS, or ICU/sub-ICU admissions.
- 86.18% of vaccinated patients had detectable anti-S antibodies (seropositive).
- Vaccinated seronegative patients had significantly higher in-hospital mortality (33.33%) than seropositive patients (10.69%).
- Higher mortality in vaccinated seronegative patients aged 45-69; comparable mortality in those ≥70.
- No outcome differences between Vg and UVg when adjusting for age and comorbidities.
Conclusions:
- Vaccination did not significantly alter outcomes between vaccinated and unvaccinated groups, considering comorbidities.
- Vaccinated individuals who were seronegative exhibited a higher mortality rate.
- Primary prophylaxis and early treatment are crucial, particularly for older and immunosuppressed populations.
Abstract:
More than 11.5 billion COVID-19 vaccine doses have been administered around the world. Although vaccine effectiveness for severe infections is reported to be 89.0%, breakthrough infections are common and may lead to severe outcome in fragile population. We conducted a real-world observational study on 420 COVID-19 admitted patients from July 2021 to January 2022 in a tertiary level Italian hospital. We collected patient's vaccination and SARS-CoV-2 serological status, SARS-CoV-2 treatments, oxygen supports, intensive (ICU) and subintensive (sub-ICU) care unit admissions, length of staying (LoS) and in-hospital mortality. One-hundred-seventy-two vaccinated and 248 unvaccinated patients were admitted during the study period. Vaccinated group (Vg) had a significantly more elevated Charlson Comorbidity Index than Unvaccinated group (UVg), and no statistical differences were found in terms of in-hospital mortality, LoS or ICU and sub-ICU admissions. Among Vg, anti-S antibodies were detected in 86.18% of patients (seropositives). Vaccinated seronegative patients' in-hospital mortality was significantly higher than vaccinated seropositive patients (33.33% vs 10.69%, p = 0.0055): in particular, mortality rate in 45-69 years old population was higher in vaccinated seronegative group, and comparable in patients ≥ 70 years old. No differences in terms of outcome were registered between Vg and UVg, taking into account that Vg was considerably older and with more comorbidities. In line with other recent observations, higher mortality rate was evidenced for seronegative vaccinated patients. Primary prophylaxis and early treatments result to be necessary, especially for older and immunosuppressed populations.
More Related Videos
Related Concept Videos
Vaccinations
Bias in Epidemiological Studies
Vaccines
Atypical Pneumonia
Cytomegalovirus Disease
Coronavirus

